RELIEF
Trial Results

About Us

BELLUS Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders.

View More

Benefits of High P2X3 Selectivity

As demonstrated in clinical trials, the inhibition of P2X3 receptors has been shown to effectively treat chronic cough. However, P2X3 antagonists with low selectivity have also been shown to negatively impact taste in a majority of patients. In our Phase 2 RELIEF clinical trial, our highly selective P2X3 antagonist, BLU-5937, resulted in a statistically significant and clinically meaningful placebo-adjusted reduction in cough frequency in high cough count patients, with little to no effect on taste.